- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A 40-week study comparing the efficacy and safety of once weekly IcoSema and daily insulin glargine 100 units/mL in participants with type 2 diabetes inadequately controlled on oral anti diabetic drugs. COMBINE 4
This study looks at a new once-a-week insulin treatment, IcoSema, for people with type 2 diabetes whose blood sugar isn't well controlled by their current medicines. It compares IcoSema to a daily insulin, glargine, to see which is better and safer.
For: Type 2 diabetesGreece · Italy · Poland - Ongoing, recruitingTherapeutic use (Phase IV)
A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 Diabetes
This study is looking at how well a new medicine, Tirzepatide, works for adults with type 2 diabetes when they switch from another medicine called Dulaglutide. Researchers want to see if the new medicine helps lower blood sugar and improve other health markers like weight.
For: Type 2 DiabetesRomania · Germany · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicentre, Randomized, Double-blind, Placebo-controlled, phase III study to evaluate the efficacy and safety of Pioglitazone co-administration in patients with type II diabetes with insufficient glycemic control with Metformin and Empagliflozin combination therapy
This study is looking at a new way to treat Type 2 diabetes. It aims to see if adding an extra medication, Pioglitazone, to a common treatment (Metformin and Empagliflozin) helps people manage their blood sugar better. It also checks if this new combination is safe.
For: Type 2 diabetes mellitus (T2DM)Poland